TWI856047B - 多聚體ｔ細胞調節多肽及其使用方法 - Google Patents

多聚體ｔ細胞調節多肽及其使用方法 Download PDF

Info

Publication number
TWI856047B
TWI856047B TW108146526A TW108146526A TWI856047B TW I856047 B TWI856047 B TW I856047B TW 108146526 A TW108146526 A TW 108146526A TW 108146526 A TW108146526 A TW 108146526A TW I856047 B TWI856047 B TW I856047B
Authority
TW
Taiwan
Prior art keywords
polypeptide
amino acid
seq
acid sequence
cases
Prior art date
Application number
TW108146526A
Other languages
English (en)
Chinese (zh)
Other versions
TW202039542A (zh
Inventor
羅納德 西德爾三世
羅多弗 加帕洛
Original Assignee
美商信號生物製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商信號生物製藥公司 filed Critical 美商信號生物製藥公司
Publication of TW202039542A publication Critical patent/TW202039542A/zh
Application granted granted Critical
Publication of TWI856047B publication Critical patent/TWI856047B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
TW108146526A 2018-12-19 2019-12-18 多聚體ｔ細胞調節多肽及其使用方法 TWI856047B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862782167P 2018-12-19 2018-12-19
US62/782,167 2018-12-19
US201962814684P 2019-03-06 2019-03-06
US62/814,684 2019-03-06

Publications (2)

Publication Number Publication Date
TW202039542A TW202039542A (zh) 2020-11-01
TWI856047B true TWI856047B (zh) 2024-09-21

Family

ID=71100921

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108146526A TWI856047B (zh) 2018-12-19 2019-12-18 多聚體ｔ細胞調節多肽及其使用方法

Country Status (18)

Country Link
US (2) US20220112252A1 (enExample)
EP (2) EP4650365A3 (enExample)
JP (1) JP7549579B2 (enExample)
KR (1) KR20210104673A (enExample)
CN (1) CN113286609B (enExample)
AU (1) AU2019404285B2 (enExample)
BR (1) BR112021011814A2 (enExample)
CA (1) CA3113100A1 (enExample)
DK (1) DK3897701T3 (enExample)
ES (1) ES3052836T3 (enExample)
IL (1) IL281505B1 (enExample)
MX (1) MX2021007287A (enExample)
MY (1) MY206813A (enExample)
PH (1) PH12021500027A1 (enExample)
SG (1) SG11202103863UA (enExample)
SI (1) SI3897701T1 (enExample)
TW (1) TWI856047B (enExample)
WO (1) WO2020132297A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017201210A1 (en) * 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
ES2973548T3 (es) 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
JP2020534352A (ja) 2017-09-07 2020-11-26 キュー バイオファーマ，インコーポレーテッド コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法
WO2021230638A1 (en) * 2020-05-12 2021-11-18 Lg Chem, Ltd. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
IL299834A (en) * 2020-07-14 2023-03-01 Cue Biopharma Inc with binding sites and methods for using them T - cellular modulatory polypeptides
WO2022099157A1 (en) * 2020-11-06 2022-05-12 Cue Biopharma, Inc. Antigen presenting polypeptide complexes and methods of use thereof
WO2022197970A2 (en) * 2021-03-19 2022-09-22 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
AU2022238389A1 (en) * 2021-03-19 2023-10-05 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
WO2023081718A1 (en) * 2021-11-04 2023-05-11 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
CN114805538B (zh) * 2022-05-20 2023-06-09 广州智瓴生物医药有限公司 一种增强til功效的培养方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015195531A2 (en) * 2014-06-18 2015-12-23 Albert Einstein College Of Medicine, Inc. Syntac polypeptides and uses thereof
WO2017201210A1 (en) * 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CN108431022A (zh) * 2015-11-20 2018-08-21 纪念斯隆凯特林癌症中心 用于治疗癌症的方法和组合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
AU687117B2 (en) 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
AU2007223855B2 (en) 2006-03-06 2013-05-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
JP2010536341A (ja) 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド 生物学的に活性なポリペプチドの特性を改変するための組成物および方法
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
US9205144B2 (en) 2011-06-03 2015-12-08 Dana-Farber Cancer Institute, Inc. Identification of conserved peptide blocks in homologous polypeptides
RS61173B1 (sr) * 2013-01-15 2021-01-29 Memorial Sloan Kettering Cancer Center Imunogeni wt-1 peptidi i postupci za njihovu upotrebu
DK3186283T3 (da) 2014-08-29 2020-03-02 Hoffmann La Roche Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1
EP4406604A3 (en) 2015-03-05 2024-10-23 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
ES2973548T3 (es) * 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
US20200010528A1 (en) * 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
CN119409836A (zh) * 2017-03-17 2025-02-11 弗雷德哈钦森癌症中心 免疫调节融合蛋白及其用途
EP3678691A4 (en) * 2017-09-07 2021-06-09 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
JP2020534352A (ja) * 2017-09-07 2020-11-26 キュー バイオファーマ，インコーポレーテッド コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法
WO2020132366A2 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
WO2020132365A2 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
EP3897690A4 (en) * 2018-12-19 2022-09-28 Cue Biopharma, Inc. T LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
CA3146591A1 (en) * 2019-09-20 2021-03-25 Ronald D. Seidel Iii T-cell modulatory polypeptides and methods of use thereof
US20230117521A1 (en) * 2020-03-25 2023-04-20 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
WO2021231376A2 (en) * 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
AU2022238389A1 (en) * 2021-03-19 2023-10-05 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015195531A2 (en) * 2014-06-18 2015-12-23 Albert Einstein College Of Medicine, Inc. Syntac polypeptides and uses thereof
CN108431022A (zh) * 2015-11-20 2018-08-21 纪念斯隆凯特林癌症中心 用于治疗癌症的方法和组合物
WO2017201210A1 (en) * 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Tafuro et al., "Reconstitution of antigen presentation in HLA class I-negative cancer cells with peptide-beta2m fusion molecules" Eur J Immunol. 2001 Feb; 31(2): 440-449 *

Also Published As

Publication number Publication date
SI3897701T1 (sl) 2025-12-31
CA3113100A1 (en) 2020-06-25
EP3897701A1 (en) 2021-10-27
PH12021500027A1 (en) 2022-05-02
EP3897701B1 (en) 2025-09-03
JP7549579B2 (ja) 2024-09-11
MX2021007287A (es) 2021-07-15
MY206813A (en) 2025-01-08
AU2019404285A1 (en) 2021-07-22
WO2020132297A1 (en) 2020-06-25
EP4650365A3 (en) 2026-02-11
US20220112252A1 (en) 2022-04-14
IL281505B1 (en) 2026-04-01
JP2022515330A (ja) 2022-02-18
AU2019404285B2 (en) 2025-10-02
BR112021011814A2 (pt) 2021-11-23
EP4650365A2 (en) 2025-11-19
KR20210104673A (ko) 2021-08-25
DK3897701T3 (da) 2025-11-03
US20250074960A1 (en) 2025-03-06
TW202039542A (zh) 2020-11-01
CN113286609A (zh) 2021-08-20
EP3897701A4 (en) 2023-01-25
IL281505A (en) 2021-04-29
ES3052836T3 (en) 2026-01-15
CN113286609B (zh) 2025-01-21
SG11202103863UA (en) 2021-05-28

Similar Documents

Publication Publication Date Title
TWI856047B (zh) 多聚體ｔ細胞調節多肽及其使用方法
JP7743428B2 (ja) 多量体ｔ細胞調節性ポリペプチド及びその使用方法
TWI856048B (zh) 多聚體ｔ細胞調節多肽及其使用方法
US20240376177A1 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
CN116096405B (zh) 多聚体t细胞调节多肽及其使用方法
US20230241192A1 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
HK40060108B (zh) 多聚体t细胞调节多肽及其使用方法
HK40060108A (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
EA049816B1 (ru) Модулирующие т-клетки мультимерные полипептиды и способы их применения
HK40089384A (zh) 多聚体t细胞调节多肽及其使用方法